Nipah Virus (NiV) Infection Testing Market (2025 - 2035)

Nipah Virus (NiV) Infection Testing Market Size and Share Forecast Outlook 2025 to 2035

The Nipah virus (NiV) infection testing market is valued at USD 2.18 billion in 2025. As per FMI's analysis, the Nipah virus (NiV) infection testing will grow at a CAGR of 5.2% and reach USD 2.63 billion by 2035. The global industry for Nipah Virus (NiV) infection testing is undergoing steady expansion powered by increasing concern over zoonotic disease outbreaks and growing investment in the development of diagnostic technologies. The segment is being fueled by the increasing demand for rapid diagnostic solutions, advancements in the molecular testing sector, and government actions to enhance infectious disease surveillance.

In 2024, the Nipah virus (NiV) infection testing sector saw continued growth due to enhanced surveillance, diagnostic technological advancements, and increased awareness after periodic outbreaks. Some nations, especially in South and Southeast Asia, increased their testing capabilities, with governments investing in early detection initiatives. The industry for polymerase chain reaction (PCR) tests remained strong due to their reliability, with rapid antigen tests gaining popularity for field diagnosis.

Furthermore, raising awareness regarding NiV infections especially in the high-risk areas like South and Southeast Asia is expected to grow the demand for early and accurate testing. The testing segment is divided into laboratory-based and point-of-care testing solutions, with the former sharing a large fraction of the sector. However, point-of-care diagnostics become advantageous due to their efficiency in outbreak settings.

Market Metrics

Nipah Virus Infection Testing Industry Analysis by Test Type and Sample Source

The Nipah virus (NiV) infection testing industry is experiencing steady growth due to several factors. More outbreaks are being screened, new diagnostic technologies are being developed, and governments are emphasizing disease preparedness. Biotech companies benefit significantly because they are developing rapid and accurate testing solutions.

Healthcare organizations also gain from this growth because they can increase the number of tests they conduct, which helps in finding infections early. Governments aim to better control infectious disease outbreaks. However, regions with weak diagnostic systems might not keep up with these advancements. The industry is expected to undergo significant changes. The companies that innovate successfully will likely lead, especially if they can make testing more accessible, develop decentralized options, or use artificial intelligence effectively.

Top 3 Strategic Imperatives for Stakeholders

Accelerate Development of Rapid and Decentralized Testing Solutions

Make investments in point-of-care diagnostics and AI-based testing solutions to increase accessibility, especially in remote areas and high-risk zones, with an aim to speed up outbreak response and containment.

Strengthen Regulatory and Industry Alignment

Partner with global health authorities and regulatory organizations to expedite approvals for novel testing solutions while harmonizing with changing disease surveillance practices and new health policies.

Expand Strategic Partnerships and Supply Chain Resilience

Form partnerships with healthcare providers, governments, and biotech companies to improve distribution networks, maximize manufacturing capacity, and provide a steady supply of high-quality diagnostic kits during outbreaks.

Top 3 Risks Stakeholders Should Monitor

1-Year Executive Watchlist

For the Boardroom

To remain at the forefront of the changing Nipah virus (NiV) testing industry, the next strategic step should be to expand rapid, decentralized testing, gain regulatory fast-tracks, and strengthen supply chains. AI-driven and portable testing investments will set the company apart in a more demand-driven world. Regulatory flexibility through forward-looking collaboration with global health authorities will speed time-to-sector for new tests.

Enhancing partnerships with biotech companies, governments, and healthcare providers will guarantee smooth distribution and manufacturing resilience. This knowledge pivots the roadmap to innovation-led growth, making the company not only keep up with increasing demand but also become a segment leader in global infectious disease diagnostics.

Future Market Insights (FMI) Survey Results on the Nipah Virus (NiV) Infection Testing Landscape

Key Priorities of Stakeholders

• Rapid and Accurate Diagnostics: 85% of stakeholders globally identified the need for faster, more reliable testing as a "critical" priority.
• Regulatory Approvals: 78% emphasized the urgency of streamlined regulatory pathways to accelerate segment entry for innovative tests.

Regional Variance:

• USA: 70% highlighted the importance of integrating AI-driven testing for automated early detection, compared to 45% in India.
• Western Europe: 82% emphasized sustainability in test manufacturing (e.g., biodegradable materials, low-energy production) vs. 50% in the USA.
• India/Southeast Asia: 68% identified affordability and accessibility as key concerns, given healthcare infrastructure disparities, compared to 30% in Western Europe.

Adoption of Advanced Testing Technologies

High Variance:

• USA: 60% of healthcare providers adopted PCR-based NiV tests due to their accuracy, driven by CDC recommendations.
• Western Europe: 55% used multiplex diagnostic platforms integrating NiV with other zoonotic disease testing.
• India: Only 28% used state advanced molecular diagnostics, citing high costs and lack of funding.
• Southeast Asia: 40% invested in portable antigen-based rapid tests for use in rural and outbreak-prone regions.

Convergent and Divergent Perspectives on ROI:

• 73% of USA and European stakeholders viewed high-precision molecular diagnostics as worth the investment, while 60% in India/Southeast Asia favored cost-effective, point-of-care tests.

Preferred Testing Methods

Consensus:

• PCR-Based Testing: Preferred by 67% globally due to its high sensitivity, especially in outbreak response.

Regional Variance:

• Western Europe: 60% leaned towards multi-pathogen panels for broader disease surveillance, compared to 35% globally.
• India/Southeast Asia: 50% preferred lateral flow antigen tests due to affordability and ease of use.
• USA: 75% continued to prioritize lab-based molecular testing, but 30% showed interest in AI-enhanced diagnostics for real-time monitoring.

Price Sensitivity

Shared Challenges:

• 89% cited rising R&D and production costs as a significant sector pressure.

Regional Differences:

• USA/Western Europe: 64% were willing to pay a 15-25% premium for high-accuracy PCR tests.
• India/Southeast Asia: 72% showed a preference for affordable test kits (< USD 10 per test) over premium solutions.
• Southeast Asia: 47% expressed interest in government-subsidized testing programs to improve accessibility.

Pain Points in the Value Chain

Manufacturers:

• USA: 58% struggled with regulatory bottlenecks delaying new test approvals.
• Western Europe: 50% cited challenges in meeting strict CE certification for diagnostic products.
• India: 62% faced supply chain disruptions due to dependence on imported reagents.

Distributors:

• USA: 72% highlighted delays in securing raw materials for test production.
• Western Europe: 55% faced competition from lower-cost Asian diagnostic suppliers.
• Southeast Asia: 68% cited logistical challenges in distributing tests to rural healthcare centers.

End-Users (Healthcare Providers & Public Health Agencies):

• USA: 46% cited high operational costs of maintaining PCR testing infrastructure.
• Western Europe: 42% faced challenges in integrating NiV diagnostics into existing disease surveillance frameworks.
• India/Southeast Asia: 60% reported inadequate training for healthcare workers in handling advanced diagnostic tools.

Future Investment Priorities

Alignment:

• 76% of global diagnostic manufacturers plan to invest in faster, decentralized testing solutions.

Divergence:

• USA: 63% in AI-powered diagnostic tools for automated detection.
• Western Europe: 58% in sustainable test manufacturing (e.g., reducing plastic waste in test kits).
• India/Southeast Asia: 52% in low-cost, easy-to-use rapid testing for outbreak control.

Regulatory Impact

USA:

• 70% of manufacturers said FDA’s evolving infectious disease guidelines significantly influenced test development timelines.

Western Europe:

• 84% viewed the European Health Union’s strengthened disease surveillance framework as a driver for faster adoption of NiV diagnostics.

India/Southeast Asia:

• Only 35% saw government policies as a major purchasing factor, citing inconsistent enforcement of public health mandates.

Conclusion: Variance vs. Consensus

High Consensus:

• Speed, affordability, and regulatory efficiency are critical factors across all regions.

Key Variances:

• USA & Western Europe: Prioritizing advanced molecular diagnostics and AI integration.
• India & Southeast Asia: Favoring affordability and widespread accessibility of rapid tests.

Strategic Insight:

• A regionally tailored approach is essential-premium molecular diagnostics in the West, while affordable, scalable testing solutions drive growth in emerging sectors.

Government Regulations Impact on the Nipah Virus (NiV) Infection Testing Landscape

Country-wise Analysis

United States

The USA NiV infection testing industry is expected to grow at a CAGR of 5.5% over the 2025 to 2035 period. Growth is aided by significant governmental allocation of research funds for infectious diseases, tough regulatory scrutiny, and a strong infrastructure for diagnostics. CDC and NIH fund the bulk of NiV research and support expansion of testing.

The EUA framework provided by the FDA facilitates the swift marketing of novel diagnostic tools during outbreaks, incentivizing biotech companies to direct resources into creating high-spec molecular assays. There are increasing instances of the uptake of both AI-powered diagnostics as well as multiplex PCR tests that can improve both speed and detection accuracy. The high healthcare expenditure and presence of global leaders in diagnostic companies including Abbott, Roche, Thermo Fisher, and others, have also contributed to the growth of the sector.

United Kingdom

With a growing focus on disease preparedness in Europe, the UK NiV infection testing sector is set to expand at a CAGR of 5.0% during the 2025 to 2035 period. Modern programs for NiV surveillance are rolled out across the UK Health Security Agency (UKHSA) and National Health Service (NHS) providing early detection and response.

EU-wide and WHO-led disease monitoring programs in which the country may participate help align regulations and obtain funds for diagnostic research. Regulatory divergence from Brexit could endanger the supply chain, with new test kits needing to be approved for use in the UK. Eco-friendly diagnostic manufacturing is gaining momentum as sustainability becomes an ever-greater priority. The UK government is encouraging public-private partnerships to create affordable, quick NiV diagnostic tests for use at the community level.

France

The growth of France’s NiV infection testing landscape between 2025 and 2035 (CAGR 4.8%) is anticipated to be slightly below the global average. With the goal of this, the country is working to expand its diagnostic infrastructure within the frame of its National Plan for Health Security and improve its zoonotic disease surveillance networks.

The French National Institute for Health and Medical Research (INSERM) also funds NiV-related studies, which encourage the design of innovative diagnostic assays. Prolonged approval processes can delay segment entry for newer diagnostic tools. NiV testing has been in growing demand over recent years due to public awareness campaigns and hospital-based surveillance programs, notably in higher risk clinical settings.

Germany

Germany’s NiV infection testing sector will continue to expand at a compound annual growth rate (CAGR) of 5.3% between 2025 and 2035, making it one of the fastest growing sectors in Europe. The strong public health infrastructure, advanced R&D capabilities, and stringent diagnostic regulations in the countries provide lucrative opportunities for the growth of the sector. NiV surveillance is driven by the Robert Koch Institute (RKI) in cooperation with the Paul Ehrlich Institute (PEI) responsible for developing and approving tests.

The smart PCR systems and digital biosensors sectors in Germany is one of the growing sectors with the presence of automated, AI diagnostics solutions. Its IVD (In Vitro Diagnostics) regulatory pathway is consistent with the European IVDR framework, delivering quality diagnostic tests. The government is directly funding zoonotic disease readiness efforts, including partnerships between biotech companies and academic researchers. Germany’s commitment to sustainable manufacturing also promotes the manufacturing of eco-friendly diagnostic kits.

Italy

Advent of government-orchestrated disease surveillance programs, and EU-mandated health security efforts, Italy's NiV infection testing industry is expected to expand at a CAGR of 4.7% over the forecast period (2025 to 2035). Multiplex diagnostic assay for the simultaneous detection of NiV and other zoonotic viruses are increasingly embraced by the Italian sector. The country needs to scale up lab infrastructure with few hospitals have advanced molecular testing capabilities.

NiV tests require CE-IVD certification, which creates an additional regulatory hurdle that prolongs approval for new diagnostics. Italy is, however, investing in regional laboratory networks and in cross border collaborations with EU health agencies. The government is also encouraging the use of inexpensive, rapid antigen tests to facilitate early detection in rural health systems. The NiV testing landscape in Italy is also set to witness gradual growth due to ongoing efforts for modernizing its disease surveillance systems.

South Korea

The South Korea NiV infection testing industry is faster to grow, while the world average is expected to reach a CAGR of 5.6% from 2025 to 2035. Rapid innovation and development of diagnostic technologies are driven by the country’s robust biotechnology sector and R&D programs supported by the government. Among them, the Korea disease control and prevention agency (KDCA) is in charge of infectious disease preparedness and allocates funds for developing new NiV tests.

South Korea is at the forefront of miniaturized, portable PCR systems and AI-facilitated diagnostics, broadening the routine tests. Test approvals are governed here by the MFDS (Ministry of Food and Drug Safety) so the tests have to meet strict quality standards. Nonetheless, the cost of state-of-the-art molecular diagnostics may limit their widespread availability. However, with increasing investments in bio surveillance systems and AI-enabled testing solutions, South Korea shall leverage to act as a destination for next-generation NiV diagnostic tests.

Japan

Japan is likely to hold a CAGR of 4.9% during the 2025 to 2035 period, which is slightly less in comparison to the global growth rate. Although India has a well-developed healthcare infrastructure and advanced diagnostic tools, the perceived low probability of Nipah virus outbreak has restricted aggressive investment in testing infrastructure.

NiV research and diagnostic test approvals are managed by the National Institute of Infectious Diseases (NIID) in collaboration with the Ministry of Health, Labour and Welfare (MHLW). The GMP license overcomes the need for PMDA approval, which can be time-consuming and is often an impediment to the commercialization of new diagnostics, especially for diseases with lower domestic incidence. In contrast, Japan is in the egg of the needle (high-throughput molecular diagnostics, automation, and AI-driven laboratory workflows).

China

During the forecast period, the China NiV infection testing industry is expected to grow with the highest CAGR globally (5.8%) between 2025 and 2035. This rapid expansion of diagnostic capabilities is driven by the country’s growing focus on infectious disease preparedness and increased investment in biotechnology. NiV surveillance, research and funding, and regulatory approval efforts are being spearheaded by the National Health Commission (NHC) and the Chinese Center for Disease Control and Prevention (CCDC).

The National Medical Products Administration (NMPA) of China has simplified the application process for in-vitro diagnostics (IVD) to facilitate rapid entry of new NiVtest kits into the Chinese sector. China’s volume-production capabilities allow it to be a global supplier of PCR kits, ELISA assays and rapid antigen tests.

Leading companies such as BGI Genomics and Wondfo Biotech are working towards affordable, high-throughput testing solutions. Government initiatives (like the Healthy China 2030 Plan) are promoting network expansion of laboratory facilities and the use of AI in diagnostics to increase the prevalence of the disease detection.

Australia & New Zealand

From 2025 to 2035, the NiV infection testing sector in Australia and New Zealand is set to expand at a CAGR of 5.4%, owing to government-initiated zoonotic disease monitoring programs and robust R&D activity for infectious disease diagnostics. Australia’s Therapeutic Goods Administration (TGA) and New Zealand’s Medsafe grant approval for diagnostic test kits, subject to strict quality standards.

Researchers from the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and the Australian Centre for Disease Preparedness (ACDP) are investigating NiV through early detection and vaccines. Australia has a high awareness and funding for bio surveillance and diagnostic preparedness given its history with zoonotic outbreaks.

Recent progress in the adoption of point-of-care (PoC) testing, there has been a growing interest and need for PoC testing for remote and indigenous communities with minimal or no access to centralized laboratories. However, the high costs of advanced molecular testing coupled with limited private sector engagement might restrain the segment growth.

India

The NiV infection testing sector in India is an exception among all countries to register highest growth with a CAGR of 6.2% during the forecast period 2025 to 2035. Regular NiV outbreaks in southern India have also created robust demand for rapid diagnostics, government detection of disease surveillance, and biosafety lab expansion. The Indian Council of Medical Research (ICMR) and National Centre for Disease Control (NCDC) are spearheading the surveillance and response efforts.

India's diagnostic sector is price-sensitive and prioritizes low-cost, high-volume testing solutions. Mylab and Trivitron, domestic biotech companies, are working on cost-effective rapid antigen tests and RT-PCR kits. The government’s Ayushman Bharat health initiative is also seeking to expand availability of infectious disease diagnostic tests in rural regions. India is set to become a leading center for NiV diagnostics in Asia under increasing government investment, private sector collaborations, and international funding.

Segment-wise Analysis

By Test Type

The CAGR for the NiV infection testing segment by test type is approximately 5.32% from 2025 to 2035. The Nipah Virus (NiV) infection testing industry is mainly divided into RT-PCR-based kits and ELISA kits, both playing different roles in diagnosis and surveillance. RT-PCR is the gold standard for early detection with high accuracy, ELISA tests offer a more scalable and affordable option for large-scale screening and epidemiological studies.

The selection of these testing measures is based on the infection stage, availability of laboratory infrastructure, and cost. The RT-PCR segment holds the largest sectors share as it can detect NiV during the early stage of an infection, making it quite useful for controlling an outbreak, as well as diagnosing patients at hospitals.

Portable and automated RT-PCR systems are in high demand due to their ease of deployment in risk-prone locations. However, cost, infrastructure requirements, and longer turnaround time are major concerns. In contrast, serological surveillance, which monitors and tests for infections and immunity over time, is often performed on samples using ELISA-based assays.

By End User

The CAGR for the NiV infection testing segment by end user from 2025 to 2035 is approximately 5.53%. By End Users (Hospitals, Research Laboratories, and Diagnostic Centers), each of which is essential for the disease surveillance, outbreak management, and long-term epidemiological studies, in The Nipah Virus (NiV) infection testing segment.

The main factors contributing to NiV testing demand include the rising number of outbreaks, introduction of government-mandated screening protocols, and technological advancement in diagnostic testing. The largest end-user segment is hospitals, as they are the first point of contact for suspected NiV cases.

The immediate need to identify and provisionally treat infected individuals has led to the adoption of RT-PCR kits for active infection detection and ELISA kits for the assessment of post-infection immunity in the laboratory and in public health settings.

Competitive Landscape

Companies are employing pricing strategies, diagnostic innovations, strategic partnerships, and global expansion as key competitive components in the overall Nipah Virus (NiV) infection testing landscape. Industry leaders are focusing on differentiation through rapid and highly sensitive diagnostic solutions, including portable RT-PCR devices, AI-assisted molecular diagnostics, and multiplex testing kits.

From a growth strategy perspective, route expansions to Asia-Pacific and Africa, where NiV outbreaks are relatively higher, are aggressively pursued by companies. Companies are using mergers, acquisitions, and partnerships with research institutions, biotech firms, and hospitals to accelerate product development and obtain regulatory approvals.

Market Share Analysis

• The Nipah virus testing industry is emerging, yet critical with diagnostics companies and biotech firms competing in this specialized space.
• Thermo Fisher Scientific leads with an estimated 25-30% industry share, driven by its RT-PCR test kits and global distribution network.
• Roche Diagnostics holds 20-25%, leveraging its high-throughput molecular testing platforms for NiV detection.
• Abbott Laboratories accounts for 15 to 20%, supported by its rapid diagnostic tests (RDTs) and portable testing solutions.
• QIAGEN and Bio-Rad Laboratories collectively hold 15 to 20%, specializing in sample preparation technologies and ELISA-based NiV testing.
• Public health agencies (CDC, NIV-Pune, etc.) and regional diagnostic manufacturers make up the remaining 10-15%, focusing on outbreak response testing.

Key Developments

• Feb 2025: Siemens Healthineers entered Nipah diagnostics with FDA-cleared automated NiV antibody test
• Nov 2024: Cepheid partnered with CEPI to develop rapid Nipah virus Xpert® cartridge for GeneXpert systems
• July 2024: South Korea approved first AI-powered Nipah screening software from Lunit for early outbreak detection
• April 2025: Merck acquired Indian biotech Virospec to expand tropical virus test portfolio
• Jan 2025: Malaysia mandated airport screening using new Nipahbreathalyzer from Owlstone Medical
• Sept 2024: WHO prequalified first African-made Nipah RDT by South Africa's Biovac

Key Players

• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• QIAGEN
• Bio-Rad Laboratories
• Siemens Healthineers
• Cepheid
• Lunit
• Owlstone Medical
• Biovac
• CDC (USA)
• NIV-Pune (India)
• CEPI (Coalition for Epidemic Preparedness Innovations)
• WHO

Key Segments

By Test Type:

It is segmented into RT PCR based kits and ELISA Kits

By End User:

It is segmented into Hospitals, Research Labs, Diagnostic Centres

By Region:

It is segmented into North America, Latin America, Europe, South Asia, East Asia, Oceania, and MEA